sur ABIVAX (EPA:ABVX)
Abivax to Hold Expert Webcast on Ulcerative Colitis
Abivax, a biotechnology company specializing in treatments for chronic inflammatory diseases, announced an upcoming webcast event scheduled for March 17, 2025. This session will focus on the treatment landscape for ulcerative colitis, featuring insights from renowned gastroenterologist Dr. David T. Rubin of The University of Chicago.
The event will delve into Abivax's ongoing ABTECT Phase 3 trial, which assesses the efficacy of obefazimod in adults with moderately to severely active ulcerative colitis. Attendees will gain insight into how this trial might address unmet medical needs in UC treatment.
The webcast, starting at 9:00 a.m. EDT (2:00 p.m. CET), will also include a live Q&A session with Dr. Rubin and Abivax’s management team. Interested participants can register online to access the virtual event.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX